Macrophage activation-like syndrome: An immunological entity associated with rapid progression to death in sepsis

BMC Medicine

Volumn 15, Issue 1, 2017, Pages

  Kyriazopoulou, Evdoxia ^a   Leventogiannis, Konstantinos ^a   Norrby Teglund, Anna ^b   Dimopoulos, Georgios ^a   Pantazi, Aikaterini ^c   Orfanos, Stylianos E ^a   Rovina, Nikoletta ^d   Tsangaris, Iraklis ^a   Gkavogianni, Theologia ^a   Botsa, Elektra ^a   Chassiou, Eleftheria ^e   Kotanidou, Anastasia ^d   Kontouli, Christina ^f   Chaloulis, Panagiotis ^g   Velissaris, Dimitrios ^h   Savva, Athina ^a   Cullberg, Jonas Sundén ^b   Akinosoglou, Karolina ^h   Gogos, Charalambos ^h   Armaganidis, Apostolos ^a   Giamarellos Bourboulis, Evangelos J ^a   more..

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Thriasion Elefsis General Hospital   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

^e G GENNIMATAS GENERAL HOSPITAL   (Greece)

^f Agios Dimitrios General Hospital   (Greece)

^g Department of Oral and Maxillofacial Surgery   (Greece)

^h UNIVERSITY OF PATRAS   (Greece)

Author keywords

Ferritin; Interleukin 18; Macrophages; Outcome; Sepsis

Indexed keywords

CD163 ANTIGEN; FERRITIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; EARLY DIAGNOSIS; FERRITIN BLOOD LEVEL; HEMOPHAGOCYTIC SYNDROME; HEPATOBILIARY DISEASE; HUMAN; IMMUNOPATHOLOGY; INFECTION; MACROPHAGE ACTIVATION LIKE SYNDROME; MAJOR CLINICAL STUDY; MORTALITY; MORTALITY RISK; PREDICTIVE VALUE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SENSITIVITY ANALYSIS; SEPSIS; SWEDISH CITIZEN; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VALIDATION PROCESS; ADULT; AGED; COMPLICATION; FEMALE; MACROPHAGE ACTIVATION SYNDROME; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; YOUNG ADULT;

ADULT; AGED; COHORT STUDIES; FEMALE; FERRITINS; HUMANS; INTERLEUKIN-18; MACROPHAGE ACTIVATION SYNDROME; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SEPSIS; YOUNG ADULT;

EID: 85029476872     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-017-0930-5     Document Type: Article

References (26)

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801-10.
2. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-74.
3. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13:260-8.
4. Opal SM, Fisher Jr CJ, Dhainaut JF, Vincent JL, Brase R, Lowry SF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med. 1997;25:1115-24.
5. Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016;44:275-81.
6. Minoia F, Davì S, Horne A, Demirkaya E, Bovis F, Li C, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014;66:3160-9.
7. Mazodier K, Marin V, Novick D, Farnarier C, Robitail S, Schleinitz N, et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood. 2005;106:3483-9.
8. Schram AM, Comstock P, Campo M, Gorovets D, Mullally A, Bodio K, et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol. 2016;172:412-9.
9. Ravelli A, Minoia F, Davi S, Horne AC, Bovis F, Pistorio A, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2016;75:481-9.
10. Calandra T, Cohen J. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med. 2005;33:1538-48.
11. Sundén-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med. 2005;33:564-73.
12. Sundén-Cullberg J, Nyström T, Lee ML, Mullins GE, Tokics L, Andersson J, et al. Pronounced elevation of resistin correlates with severity of disease in severe sepsis and septic shock. Crit Care Med. 2007;35:1536-42.
13. Linder A, Akesson P, Inghammar M, Treutiger CJ, Linner A, Sunden-Cullberg J. Elevated plasma levels of heparin-binding protein in intensive care unit patients with severe sepsis and septic shock. Crit Care. 2012;16:R90.
14. Giamarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V, Savva A, Tsangaris I, Dimopoulou I, et al. Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor. Crit Care. 2012;16:R149.
15. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66:2613-20.
16. Taylor FB, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327-30.
17. Giamarellos-Bourboulis EJ, Tsaganos T, Tsangaris I, Lada M, Routsi C, Sinapidis D, et al. Validation of the new sepsis-3 definitions: proposal for improvement in early risk identification. Clin Microbiol Infect. 2017;23:104-9.
18. Lehmberg K, McClain KL, Janka GE, Allen CE. Determination of an appropriate cut-off value for ferritin in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2014;61:2101-3.
19. Kostik M, Dubko M, Masalova V, Snegireva L, Kornishina T, Chikova I, et al. Identification of the best cut off points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis. Semir Arthr Rheum. 2015;44:417-22.
20. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229-65.
21. Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D'Cruz DP, Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013;11:185.
22. Dinarello C, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol. 2013;4:289.
23. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis. 2000;181:176-80.
24. Monneret G, Finck ME, Venet F, Debard AL, Bohé J, Bienvenu J, Lepape A. The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol Lett. 2004;95:193-8.
25. Cairo G, Recalcati S, Mantovani A, Locati M. Iron trafficking and metabolism in macrophages: contribution to the polarized phenotype. Trends Immunol. 2011;32:241-7.
26. Colafrancesco S, Priori R, Alessandri C, Astorri E, Perricone C, Blank M, et al. The hyperferritinemic syndromes and CD163: a marker of macrophage activation. Isr Med Assoc J. 2014;16:662-3.